Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular
endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent
inhibitory effects on multiple human tumor xenografts. Combined with hepatic arterial
infusion chemotherapy (HAIC), this study is conducted to assess the efficacy and safety of
this regimen in patients with unresectable colorectal cancer liver metastases as the
third-line therapy.